The tumor necrosis factor receptor superfamily member HVEM is one of the most frequently mutated surface proteins in germinal center (GC)-derived B cell lymphomas. We found that HVEM deficiency increased B cell competitiveness during pre-GC and GC responses. The immunoglobulin (Ig) superfamily protein BTLA regulated HVEM-expressing B cell responses independently of B-cell-intrinsic signaling via HVEM or BTLA. BTLA signaling into T cells through the phosphatase SHP1 reduced T cell receptor (TCR) signaling and preformed CD40 ligand mobilization to the immunological synapse, thus diminishing the help delivered to B cells. Moreover, T cell deficiency in BTLA cooperated with B cell Bcl-2 overexpression, leading to GC B cell outgrowth. These results establish that HVEM restrains the T helper signals delivered to B cells to influence GC selection outcomes, and they suggest that BTLA functions as a cell-extrinsic suppressor of GC B cell lymphomagenesis.
In Brief
HVEM is one of the most frequently mutated surface proteins in germinalcenter-derived B cell lymphomas. Mintz et al. find that T cell help is restrained by the interaction between HVEM on B cells and BTLA on T follicular helper cells. Loss of the HVEM-BTLA axis leads to increased B cell competitiveness, a reduced stringency of selection, and outgrowth of pre-malignant B cells. (Bannard and Cyster, 2017; Mesin et al., 2016) . However, which factors beyond major histocompatibility complex (MHC) class II-peptide amounts determine the quantity and quality of help delivered to GC B cells is incompletely understood. The tumor necrosis factor (TNF) receptor superfamily member HVEM (encoded by the gene TNFRSF14) is the most highly mutated surface molecule in GC-derived follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) (Cheung et al., 2010; Lackraj et al., 2018; Launay et al., 2012; Manso et al., 2017; Schmitz et al., 2018) . HVEM is expressed in B cells as well as several other cell types and has multiple ligands. Two ligands, LIGHT and LTa3, are members of the TNF superfamily, whereas two other ligands, BTLA and CD160, are members of the immunoglobulin (Ig) superfamily. BTLA and CD160 bind HVEM's first cysteine-rich domain (CRD1), whereas LIGHT binds CRD2 (Ward-Kavanagh et al., 2016) . HVEM contains TRAF-binding motifs in its cytoplasmic tail, and cross-linking of HVEM can lead to downstream signaling via NFkB (Cheung et al., 2009b; Hsu et al., 1997; Shui et al., 2012) . In addition to acting as a receptor and transducing intracellular signals, HVEM can act as a ligand and transmit signals into BTLA-expressing cells (Sedy et al., 2005) .
BTLA is widely expressed by immune cells and is highly expressed on B cells, dendritic cells (DCs), and some effector T cells (Murphy et al., 2006) . BTLA contains ITIM (immunoreceptor tyrosine-based inhibition) motifs in its cytoplasmic domain and can recruit both SH2-domain-containing tyrosine phosphatases SHP1 and SHP2, but not SHIP or SAP (Chemnitz et al., 2004; Gavrieli et al., 2003; Steinberg et al., 2011; Watanabe et al., 2003) . BTLA can negatively regulate both T cell receptor (TCR) and B cell receptor (BCR) signaling in vitro (Vendel et al., 2009; Wu et al., 2007) and can be recruited to the immune cell interface (Owada et al., 2010) . BTLA also contains a Grb2 binding site that might promote CD8 + T cell cytokine production and proliferation (Ritthipichai et al., 2017; Wakamatsu et al., 2013) .
Therefore, the signaling actions of BTLA might differ between different cell populations and need to be defined on a celltype-by-cell-type basis.
BTLA is a Tfh cell marker, yet its role in these cells is not well defined (Chtanova et al., 2004; Nurieva et al., 2009 ). In one study,
Btla
À/À T cells supported a slightly greater IgG2a and IgG2b response following OVA immunization (Kashiwakuma et al., 2010) . In a recent study, small hairpin RNA (shRNA) targeting of Hvem in a Bcl-2-driven model of FL increased lymphomagenesis (Boice et al., 2016) . Hematopoietic shRNA targeting of Btla also increased lymphomagenesis, and the authors suggest that this reflects a function of HVEM within B cells engaging BTLA in B cells to transmit BTLA-mediated BCR-repressive signals.
Whether such signals occur in normal GC B cells remains unclear.
Here, we found that HVEM acts to restrain B cell participation in the GC response by signaling via BTLA on T cells. HVEM deficiency provided a proliferative advantage to B cells as early as day 3 or 4 of the response. HVEM engagement of BTLA on T cells decreased TCR signaling and the amount of preformed CD40L mobilized to the T cell surface. Thus, HVEM on B cells restrains T cell help to influence GC selection outcomes, and interfering with this regulatory axis provides a competitive advantage in GC B cell lymphomagenesis.
RESULTS

HVEM Deficiency Increases GC B Cell Competitiveness
Hvem (Tnfrsf14) transcripts were expressed at similar levels in follicular and GC B cells ( Figure 1A ), and HVEM was present on the surface of both cell types, though at lower levels on GC B cells ( Figure 1B ). To test whether HVEM is an intrinsic regulator of GC B cell responses, we generated mixed-bone-marrow (BM) chimeric mice where BM from wild-type (WT) CD45.1 donor mice was mixed with CD45.2 BM from Hvem +/À or Hvem À/À mice.
After immunization with sheep red blood cells (SRBCs), HVEMdeficient B cells were represented more in GCs than in the follicular compartment ( Figure 1C and Figure S1A ). HVEM heterozygosity led to an intermediate phenotype ( Figure 1C ). The participation of Hvem À/À B cells in the follicular compartment matched that of developing B cells in the BM ( Figure S1B ). HVEM deficiency also provided GC B cells with increased competitiveness in chronic GCs in the mesenteric lymph node and Peyer's patches ( Figure S1C ). Hvem À/À B cells were similarly over-represented in the light and dark zones of the GC ( Figure S1D ). Although HVEM deficiency gave GC B cells a competitive advantage in the mixed setting, it did not lead to a significant increase in GC size in competitive or non-competitive conditions (Figures S1E and S1F).
To permit tracking of antigen-specific B cells during the GC response, we immunized mixed BM chimeras with the haptenated antigen NP-CGG in alum adjuvant. In the GC response at day 6 or 7 after immunization, HVEM-deficient B cells were more frequent in GCs than in the follicular compartment (Figure 1D) . Notably, this advantage was more pronounced in the non-hapten binding (NP À ) GC B cells than in the NP + fraction ( Figure 1D ). HVEM-deficient GC B cells maintained approximately the same magnitude of advantage over the course of the GC response through day 21 ( Figure 1D ). The frequency of NP + GC B cells was similar between full Hvem À/À animals and WT littermate controls, suggesting that there is not a baseline repertoire difference (Figures S1G and S1H). Paired-end RNA sequencing and BCR gene-usage analysis through MIXCR (Bolotin et al., 2015) at day 11 of the response Figure S1 .
showed that Hvem À/À GC B cells used Iglv1, the canonical l chain expanded during NP responses in C57BL/6 mice, less than their WT competitors ( Figure 1E ). We performed PCR on sorted GC B cells from mixed BM chimeras to examine the frequency of high-affinity mutations in the canonical NP-responding gene VH186.2 at days 11-13. When referenced against the WT mixed chimeras, HVEM-deficient GC B cells had a lower stringency in selection for the W33L mutation than WT GC B cells in the same animal ( Figure 1F ). The SRBC-immunized mixed BM chimeras showed more HVEM-deficient than WT memory B (Bmem) cells and plasma cells (PCs) at day 8 ( Figures S1A and S1I ). HVEM deficiency also increased the frequency of NP + Bmem cells and PCs at days 7-21 of the NP-CGG response ( Figure S1J ). These data suggest that Bmem cells and PCs were generated approximately in proportion to the GC cells. Additionally, HVEM deficiency did not affect the frequency of IgG1 + class-switched B cells in the GC ( Figure S1K ). One mechanism by which HVEM deficiency could lead to increased GC B cell accumulation is by reduced cell death. However, the frequencies of apoptotic HVEM-deficient and WT GC B cells as measured by active caspase-3 were similar ( Figure S1L ). These findings led us to consider whether B cell proliferation might be affected.
HVEM Deficiency Provides the Earliest GC B Cells with a Proliferation Advantage
To determine whether HVEM deficiency increases B cell entry into the GC, we crossed the Hvem À/À mouse line to the Hy10 mouse line, which has a BCR specific to hen egg lysozyme (HEL). To test whether Hvem À/À B cells proliferate more than their competitors during the early response, we labeled Hvem À/À and WT Hy10 B cell mixes with cell trace violet (CTV), co-transferred them with OVA-specific OT-II CD4 + T cells into WT hosts, and immunized the mice with HEL-OVA or the lower-affinity antigen DEL-OVA (Figure 2A ). At day 2, the amount of proliferation in each group was similar, but by day 3, Hvem À/À Hy10 B cells had an increased frequency of cells that had divided greater than four times, as measured by the increase in CTV lo cells (Figures 2B and 2C) . The responses to high-and low-affinity forms of the antigen were similar (Figure 2C) . When the proliferation rates were referenced against those in the control mixed transfers, the proliferation rate of the WT cells that were in competition with the HVEM-deficient cells appeared decreased ( Figure 2C ). At days 4.5-5 after immunization, when both plasmablasts (PBs) and GC B cells could be clearly identified by flow cytometry ( Figure S2A ), Hvem À/À Hy10 B cells were more frequent in the GC compartment than their WT competitors ( Figure 2D ). There was also an increase in the PB compartment, though this effect was often not as marked as for the GC B cells in the same animals ( Figure 2D ). Figure 2G ). A 1 hr EdU labeling analysis showed that a slightly greater fraction of HVEM-deficient than internal control GC B cells were proliferating ( Figure 2H HVEM Signaling Intrinsic to the B Cell Is Not Required for GC B Cell Suppression To test whether HVEM signaling into the B cell is required for HVEM-mediated restraint of the GC response, we used a gainof-function approach. BM-chimeric mice were generated with BM that had been transduced with MSCV-Thy1.1 retrovirus encoding full-length or mutated forms of Hvem, and the reconstituted mice were immunized with SRBCs ( Figures 3A-3C ). After overexpression of WT HVEM, Thy1.1 reporter + GC B cells were 50% less represented than follicular B cells, whereas overexpression of an empty vector did not alter Thy1.1 + B cell participation in the GC ( Figures 3C and 3D ).
To determine whether loss of HVEM's ability to recruit TRAF2/ 5 affects GC B cell participation, we introduced a point mutation that is known to disrupt TRAF recruitment, E271A, into the HVEM cytoplasmic tail (Hsu et al., 1997) . This mutant form of HVEM was expressed on the cell surface and repressed B cell participation in the GC to the same extent as WT HVEM (Figures 3B-3D ). To rule out signaling via other parts of the HVEM cytoplasmic tail, we generated a mutant harboring a stop codon at position 235 (D235) immediately after the transmembrane domain. This construct suppressed B cell participation in the GC similarly to the WT (Figures 3B-3D ). The D235 mutant also restrained B cell participation in the GC when expressed in Hvem À/À cells ( Figure 3E ). These data demonstrate that HVEM's intrinsic signaling into the B cell is not required for its ability to restrain B cell participation in the GC response.
A point mutation at Y61A within the HVEM CRD1 disrupts binding to BTLA and CD160 (Cheung et al., 2009a) . Unlike WT HVEM, Y61A HVEM failed to reduce the participation of transduced B cells in the GC response, suggesting that HVEM's ability to bind a ligand through CRD1 is required ( Figures 3F  and 3G ).
BTLA on CD4
+ T Cells Is Required for HVEM-Deficient
GC B Cell Competitiveness
Given that BTLA is an inhibitory receptor highly expressed in the GC on both B cells and T cells ( Figure 4A ), we tested whether BTLA is required for HVEM's suppressive ability. When HVEM was overexpressed in Btla À/À BM-chimeric mice, Thy1.1 reporter + GC B cells participated in the GC at the same frequency as in follicular B cells ( Figure 4B ). This finding contrasts Figure S2 .
with the repressive effect of HVEM overexpression on B cells in WT BM-chimeric mice ( Figure 3D ) and suggests that BTLA is the relevant ligand for HVEM's ability to suppress participation in the GC.
In vitro studies have shown that BTLA in B cells can inhibit BCR signaling, and it has been suggested that HVEM-BTLA can interact in cis within the same cell (Cheung et al., 2009a; Vendel et al., 2009) , and a role for such cis interactions has been invoked to explain findings in a mouse FL model (Boice et al., 2016; Huet et al., 2018; Verdiè re et al., 2018) . If the actions of HVEM in restraining B cell participation in the GC were dependent on cis engagement with BTLA, B cells lacking BTLA would be predicted to have a GC growth advantage similar to that observed for HVEM-deficient cells. Analysis of mice reconstituted with a mixture of WT and Btla À/À BM showed that cell-intrinsic loss of BTLA did not alter the frequency of B cells in the GC ( Figure 4C ). Similar results were obtained when mixed BM chimeras were made with BM from Btla
Mb1
Cre mice that selectively lack BTLA in B cells (Figures S3A and S3B).
To determine whether BTLA on bystander B cells acts in trans to influence antigen-reactive B cells, we transferred Hvem À/À and WT Hy10 B cell mixes into Btla f/f Mb1 Cre or control hosts that were then immunized with 23-HEL-SRBC ( Figure 4D ). Hvem À/À Hy10 B cells maintained their growth advantage in the BTLA-B-cell-deficient hosts, suggesting that bystander B cells are not the cellular source of BTLA for HVEM-mediated suppression of GC B cell participation ( Figure 4E ). BTLA is a defining marker on Tfh cells compared with other CD4 + T cells ( Figure 4A ) (Chtanova et al., 2004; Kashiwakuma et al., 2010; Nurieva et al., 2009) . To test whether HVEM-deficient GC B cell competitiveness requires BTLA-expressing T cells, we transferred Hvem À/À and WT Hy10 B cell mixes into Btla f/f Cd4 Cre hosts that lack BTLA in all T cells ( Figure S3A ).
The hosts were immunized with 23-HEL-SRBC and analyzed at days 3-6 of the response ( Figure 4D ). The Hvem À/À Hy10 GC B cell growth advantage was abrogated in BTLA-T-celldeficient mice at all time points analyzed ( Figure 4F and Figure S3C ). Tfh cells were present at similar frequencies in both A previous study reported that BTLA deficiency led to increased IL-21 production by in-vitro-generated and -restimulated Tfh cells (Kashiwakuma et al., 2010) . However, when Tfh cells were generated in vivo, we did not observe a difference in Il21 expression between BTLA-deficient and WT Tfh cells from the same animals ( Figure S3I ).
BTLA-HVEM at the Immunological Synapse Recruits SHP1 to Inhibit Signaling in Tfh Cells
To determine whether BTLA can alter CD4 + T cell signaling at the immunological synapse when it engages HVEM, we turned to the well-established supported lipid bilayer model (Dustin et al., 2007) . Human CD4 + T cell blasts were transfected with BTLA to mimic the surface expression in Tfh cells ( Figure S4A ) and settled on supported lipid bilayers containing anti-CD3 (UCHT1) and ICAM1 for 15 min before fixation. When HVEM was added to the bilayers, BTLA and HVEM were recruited to the synapse and formed a ring around the central synaptic cleft in cases where a stable synapse had been formed ( Figure 5A ). In the presence of HVEM, there was a shift in interface organization from the stable synapse to the motile kinapse state (Mayya et al., 2018) , where the TCR cluster was at one pole of the interface ( Figure 5B and Figure S4B ).
BTLA has been shown to recruit SHP1 and SHP2 biochemically through Y257 and Y282 Watanabe et al., 2003) . BTLA demonstrated strong colocalization with SHP1 at the synapse, whereas SHP2 did not preferentially colocalize ( Figures 5C-5F ). When the CD4 + T cells blasts were transfected with a BTLA Y257F/Y282F mutant, SHP1 colocalization was diminished and SHP2 was unchanged ( Figures 5C-5F ). The incomplete effect on SHP1 recruitment most likely reflects the activity of endogenous BTLA in the blasts. These results contrast with the PD-1 molecule that colocalizes preferentially with SHP2 at the synapse ( Figures S4C-S4F ).
In accord with SHP1 recruitment, inclusion of HVEM in the bilayer inhibited the amount of signaling downstream of the TCR, as measured by pZAP70 and pPKCq . This was observed for both BTLA-transfected CD4 + T cells and human tonsil-derived Tfh cells . Inclusion of the CD28 ligand CD80 in the bilayer led to an elevated amount of signaling, and HVEM continued to reduce, in most cases significantly, the extent of ZAP70 and PKCq activation . These data suggest that HVEM engagement of BTLA inhibits T cell activation through SHP1 at the immunological synapse.
BTLA Signaling into the T Cell through SHP1 Is Required for HVEM-Deficient GC B Cell Competitiveness
To test whether BTLA signaling restrains the help provided to B cells, we generated a mutant mouse line (termed BTLA Y3) that lacks the BTLA cytoplasmic tail ( Figure 6A and Figure S5A ). Hvem À/À Hy10 spleen cell mixes were then transferred into Btla
, and Btla À/À hosts, and the mice Tfh cell frequencies in the SHP1 and SHP2 T-cell-deficient hosts were similar to those in controls ( Figures S5C and S5D ). The Hvem À/À GC B cell competitive advantage was lost in SHP1
T-cell-deficient hosts, whereas it was maintained in SHP2
T-cell-deficient hosts ( Figures 6C and 6D ). The frequency of HEL-binding B cells in both host types was comparable to that in controls (Figures S5E and S5F) . These data suggest that after HVEM engagement, BTLA recruits SHP1 to moderate the activation of the T cell and the amount of help provided to the HVEMexpressing B cell.
HVEM-BTLA Interaction Reduces the Amount of CD40-CD40L Brought to the Synaptic Interface For a Tfh cell to provide greater help to HVEM-deficient B cells than to HVEM-expressing B cells in the same GC microenvironment during interactions that often last only a few minutes, Tfh cell BTLA most likely has to regulate the mobilization of a preformed mediator. The best defined pre-formed helper factor in Tfh cells is CD40L (Casamayor-Palleja et al., 1995; Koguchi et al., 2007; . However, it has been unclear whether the amount of preformed CD40L displayed on the T cell surface can be tuned by the strength of the TCR signal. As one approach to test this, we incubated OVA-specific OT-II Tfh cells for 30 min with B cells that had been pulsed with a range of OVA-peptide concentrations. A 30 min incubation was chosen as a time that allowed cells to interact in the in vitro environment while being sufficiently short to ensure that only preformed CD40L could be mobilized. Although the B cells were not intentionally activated, they expressed ICOSL (Xu et al., 2013) and upregulated CD86 during the incubation ( Figure S5G) Figures 6G and 6H) . Past studies have shown that CD40 is recruited to the immune synapse in a CD40L-dependent manner (Boisvert et al., 2004; Papa et al., 2017) . We therefore returned to the supported lipid bilayer as another approach to test the ability of BTLA to regulate preformed CD40L upregulation. Human CD4 + T cell blasts and human Tfh cells were plated on the bilayer containing anti-CD3, ICAM1, CD40, and in some cases CD80. When HVEM was added to the bilayer, the amount of CD40 recruited to the synapse in the 15 min assay was reduced in both the blasts and the Tfh cells ( Figures 6I and 6J and Figure S5J ). These data suggest that BTLA can restrain the amount of preformed CD40L that is mobilized to the immunological synapse and thus the quality of T cell help. To examine whether increased T cell help could be read out in the Hvem À/À GC B cell as a transcriptional change, we performed RNA sequencing on GC B cells from mixed BM chimeras. The top differentially expressed genes in Hvem À/À GC B cells compared with WT GC B cells corresponded to Gene Ontology biological processes for positive regulation of cell-cycle progression ( Figure S5K ). Previous studies have shown that Tfh cell help signals through CD40 to activate Myc and mTOR1 signaling in GC B cells (Calado et al., 2012; Dominguez-Sola et al., 2012; Ersching et al., 2017; Luo et al., 2018) . Gene-set enrichment analysis (GSEA) revealed that Hvem À/À GC B cells had more
Myc gene signatures than their WT competitors ( Figure S5L ) (Yu et al., 2005) . Hvem À/À GC B cells were also enriched with a set of rapamycin-sensitive genes induced downstream of T cell help in GC B cells ( Figure S5M ) (Ersching et al., 2017 Figure 7A ). These data indicate that the growth-promoting pathway mediated by HVEM deficiency is distinct from the pro-survival pathway mediated by Bcl-2. Bcl-2 is very highly expressed in human FL, and previous work has shown that lines of mice expressing higher amounts of Bcl-2 in B cells than the BCL2-tg line have a higher propensity to form lymphomas (Ogilvy et al., 1999) . To generate mice with higher expression of Bcl-2 in B cells, we transduced WT or Hvem À/À BM with a MSCV-Bcl2-Thy1.1 construct. After we reconstituted WT hosts, the Bcl-2-overexpressing BM chimeras generated large splenic GCs in unimmunized mice as early as week 6 after reconstitution, and the GCs increased in size through 14 weeks ( Figures 7B and 7C) . Compared with WT chimeras, Hvem À/À chimeras had increased GC B cell expansion, suggesting that HVEM deficiency cooperates with strong Bcl-2 overexpression.
On the basis of our findings in the preceding sections, we hypothesized that BTLA in the T cell could restrain the amount of help provided to the GC B cell in the setting of Bcl-2 overexpression. To test this possibility, we transduced Btla f/f Cd4 Cre or control BM with the MSCV-Bcl2-Thy1.1 construct and used it to reconstitute Rag2 À/À or Tcrb À/À mice. We used T-cell-deficient mice as hosts to ensure an absence of radioresistant WT T cells. When Bcl-2-overexpressing B cells developed in an environment where all the T cells were BTLA deficient, there was increased GC B cell expansion in the spleen (Figures 7D-7F ).
VH-and VL-region PCR analysis of GC B cells from two of the
Cre BM chimeras with GC B cell frequencies exceeding 20% of splenic B cells showed evidence of clonal outgrowths ( Figure 7G ). Clonal dominance was not observable for the light chain, perhaps because even small numbers of polyclonal cells prevent an abundant clone from dominating this PCR reaction. All together, these data indicate that BTLA on the T cell acts as a cell-extrinsic suppressor of Bcl-2-overexpressing GC B cell expansion.
DISCUSSION
The above findings establish that engagement of BTLA on helper T cells by HVEM on B cells signals to restrain B cell expansion during the generation of GC cells and PBs and also acts as a restraint on B cells within the GC. The negative signaling into the T cell depends on the BTLA cytoplasmic domain and on SHP1 recruitment. HVEM engagement of BTLA reduces proximal TCR signaling, and this reduces the output of CD40L and most likely other preformed mediators from the T cell. HVEM thereby restrains B cell proliferation, differentiation, and selection by reducing the delivery of helper signals from the T cell. We also found that the T helper signals restrained by the HVEM-BTLA interaction can exert their growth-promoting effects on Bcl-2-overexpressing (pre-malignant) B cells, providing evidence that BTLA might act as a cell-extrinsic repressor of B cell lymphomagenesis. Under competitive conditions, proliferation of HVEM-deficient B cells was favored over that of WT B cells, in agreement with other models of B cell competition for T cell help (Gitlin et al., 2014; Schwickert et al., 2011; Zaretsky et al., 2017; Ersching et al., 2017; Yeh et al., 2018) . When C57BL/6 mice were deficient in HVEM in all B cells or deficient in BTLA in all T cells, although there was a trend toward increased GC frequencies, the GC response was not significantly enlarged. A study in BALB/c mice reported an enlarged GC response when BTLA was absent, suggesting that the extent of BTLA-mediated regulation of GC B cells might be influenced by background genes (Kashiwakuma et al., 2010). Although we observed a slight increase in Hvem À/À GC B cell proliferation in mixed settings across several time points, we did not observe a progressive increase in Hvem À/À B cell representation within the GC over time, suggesting there should be increased output of Hvem À/À cells from the GC to account for the extra cells generated by proliferation. Our inability to detect more GC B cell death or more Bmem or PC representation than B cell representation in the GC could be because of a small effect size and the possibility that more than one of these output parameters is affected. In addition to leading to increased proliferation of HVEM-deficient cells, lack of HVEM on some B cells appeared to reduce proliferation of competing WT B cells in the same animal. The exact mechanism of the diminished response of the WT cells is unclear, but one possibility is that Tfh cells harbor a limited amount of preformed helper factors (such as CD40L), and when greater amounts are delivered to some cells (Hvem À/À in this case), less is available for the other cells present in the same microenvironment. A related possibility, suggested by the propensity of HVEM to convert stable synapses to motile kinapses, is that the increased stability of Hvem À/À B cell interactions with Tfh cells diminishes the contact of WT B cells with Tfh cells.
B-T interactions generally occur over periods of minutes, making it unlikely that there is sufficient time for B-cell-triggered induction of new transcription to affect the T cell help delivered during a given contact. Although previous studies have shown that CD40L can be upregulated in a graded manner in proportion to the amount of TCR engagement, these studies were done over periods of 16-20 hr and most likely involved transcriptional induction (Iezzi et al., 2009; Ruedl et al., 2000) . In our study, we found that the rapid display of preformed CD40L on Tfh cells occurred in a manner proportional to the amount of MHC peptide on the B cells. In accordance with the fact that stronger signaling into the T cell mobilizes more preformed CD40L, previous work found that co-engagement of ICOS and the TCR enhances CD40L externalization (Liu et al., 2015; Papa et al., 2017) . These combined observations suggest that the BTLA-mediated restraint of TCR-induced CD40L mobilization in T cells is due to the negative regulation of proximal TCR signaling.
In biochemical studies, BTLA co-immunoprecipitates with SHP1 and SHP2 Watanabe et al., 2003) . The molecular basis for the preferential coupling to SHP1 observed here in Tfh cells is not yet known and will need further investigation. These observations contrast with findings for PD-1, which preferentially associates with SHP2 in immune synapse studies with CD4 + and CD8 + T cells (Hui et al., 2017; Yokosuka et al., 2012 ; this study). However, an in vivo study suggests that PD-1 function in effector CD8 T cells is not fully dependent on SHP2 (Rota et al., 2018) . Given that PD-1 and BTLA are both highly expressed on Tfh cells, it will be important to determine whether PD-1 in Tfh cells in vivo depends on SHP2 because this could indicate qualitative differences in the type of regulation exerted in Tfh cells by these related checkpoint-family proteins. HVEM-mediated restraint of the B cell response did not begin immediately, suggesting that some temporal event needs to take place before HVEM-BTLA signaling becomes influential. We speculate that this could at least in part reflect the need for Bcl6 and BTLA upregulation in the activated T cell given that the influence of HVEM deficiency was lost in mice lacking Bcl6 in T cells. It is notable that HVEM surface levels are lower on both mouse and human GC B cells than on naive and early activated B cells. Given the strong growth-repressive effects observed in HVEM gain-of-function experiments, the reduced HVEM levels could be important in permitting transmission of the helper signals needed to support the strong proliferative responses of GC B cells.
Predicting the impact of greater T cell help (indiscriminate of the amount of MHC peptide presented) on the repertoire of B cells selected in the GC is not straightforward. We found that selection of NP-binding B cells was disfavored in HVEM-deficient B cells, perhaps indicating an increased competitiveness of carrier-specific B cells that would normally receive inadequate T cell help and be outcompeted by B cells responding to the readily accessible and highly multivalent NP hapten. Our inability to detect a differential effect of HVEM deficiency on the proliferative response of Hy10 B cells responding to DEL (K A 10 7 M À1 )
versus HEL (K A 10 10 M À1 ) (Lavoie et al., 1992) could be because both antigens are in the high-affinity range, and the oligomeric state of the OVA conjugates could further diminish differences in antigen capture and MHC peptide presentation. In the context of NP-based immunizations, a similar increase in representation of non-NP binding B cells has been seen in immunized PD-L1-deficient mice (Shi et al., 2018) . The fraction of cells harboring the affinity-improving W33L mutation was lower within the NPbinding Hvem À/À GC B cell population than in the internal control WT cell population. It was notable that W33L mutations were more frequent in the WT cells competing with Hvem À/À cells than in those competing with other WT cells. One interpretation of these findings is that by diminishing the helper signals available to WT B cells, the HVEM-deficient B cells promote stronger selection for those WT B cells that are able to present the highest amounts of antigen. The combined observations suggest that negative costimulatory molecule signaling in Tfh cells is necessary to maintain the stringency of GC selection. A reduction in B cell selection stringency could explain the autoantibody production that occurs in aged BTLA-deficient 129/SvEV mice (Oya et al., 2008) In agreement with a previous study on Bcl-2-overexpressing BM chimeras (Boice et al., 2016) , in which Hvem shRNA-targeted B cells preferentially contributed to GC-derived lymphomas, we found that B cell HVEM deficiency cooperated with Bcl-2 overexpression in promoting GC outgrowth. The authors of the previous study also found that shRNA targeting of Btla in hematopoietic cells (HSCs) led to GC lymphomas and attributed this to a mechanism whereby cis engagement of BTLA by HVEM leads to BTLA-mediated downregulation of tumor-promoting BCR signals (Boice et al., 2016; Huet et al., 2018 ; Verdiè re et al., 2018). In the experiments here, we did not observe any evidence for cis or trans effects of deleting BTLA from B cells, as measured by participation in the GC response. Instead, we found that deletion of BTLA from T cells led to a growth advantage for HVEM-expressing B cells, including in the setting of Bcl-2 overexpression. Although an important distinction between these studies is that we measured GC participation and Boice et al. measured B cell lymphomagenesis, we believe that the different conclusions can be reconciled. Specifically, Boice et al. did not report enrichment of shRNA-Btla B cells over control B cells in BM chimeras, making it seem unlikely that cis HVEM-BTLA interaction could be the principle mechanism of HVEM-mediated tumor suppression. Although they also proposed trans engagement by HVEM expressed in other B cells (Boice et al., 2016) , we believe a more likely explanation for the lymphomas arising in some of the chimeras with shRNA-Btla HSCs is that Btla transcripts are reduced in the Tfh cell compartment. We believe that our findings together with Boice et al.'s shRNA chimera data support a revised model in which HVEM mutation in B cells leads to a loss of negative signaling in Tfh cells and allows HVEM-mutant B cells to receive exaggerated helper signals that promote proliferation and accrual of activation-induced cytidine deaminase (AID)-mediated mutations. In this regard, it is notable that FL is known for its rich presence of Tfh cells (de Jong and Fest, 2011; Huet et al., 2018; Verdiè re et al., 2018) . Importantly, the therapeutic benefit of elevating HVEM levels in the FL setting, as Boice et al. (2016) achieved, by using CAR T cells might act by diminishing Tfh cell function and thus support FL cell growth. Future studies are needed to test whether soluble HVEM can reduce Tfh cell function during GC responses and in lymphoma models where B cell HVEM has been mutated.
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jason G. Cyster (jason.cyster@ucsf.edu). The mouse lines obtained from other laboratories are described below and may require a Material Transfer Agreement (MTA) with the providing scientists. BTLAY3 mice generated in this study are available from our laboratory, also with an MTA.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice Adult C57BL6 CD45.1 mice at least 7 weeks of age were from the National Cancer Institute. Hvem flox animals (JAX stock 030862) and Hvem-deficient animals (Seo et al., 2018) were used in most studies. In one experiment mixed chimeras were generated from a separate Hvem-deficient line (Wang et al., 2005) . Btla flox animals have loxp sites flanking exons 4 and 5 of Btla gene (J.-W.S. and M.K., unpublished data). Full Btla deficient mice were from JAX stock 006353 . Other lines included Ptpn6 flox (JAX stock 008336), Ptpn11 flox (JAX stock 025758), Bcl6 flox (JAX 023727), Cg1-Cre (JAX stock 010611), S1pr2-ERT2Cre tdTomato Flox (Shinnakasu et al., 2016) , Mb1-Cre (JAX stock 020505), Cd4-Cre (JAX stock 022071), Hy10 (Allen et al., 2007) , OT-II (MGI 4836972), and Rag2 À/À (JAX stock 008449), Tcrb À/À (JAX stock 002118), Em-BCL2-tg (JAX stock 002319), and Btla-y3/y3 animals were generated and maintained in our laboratory. In most experiments, littermates were used as controls and experimental animals were co-caged in groups of 2-6 whenever possible. Male and female mice were used as both donors and recipients, except for OT-II animals, which required male donors. Animals were housed in specific pathogen free environment in the Laboratory Animal Research Center at UCSF and all experiments conformed to ethical principles and guidelines approved by the UCSF Institutional Animal Care and Use Committee.
METHOD DETAILS Generation of BTLAY3 Mice
Btla-y3/y3 animals were generated using crRNA1:TCATAAATTCCAGTTCCTGA targeting guide. The protocol followed Chen et al. (Chen et al., 2016) with the main exception that the standard square curve electroporation was performed twice with an interval of 3 s. RNP assembly followed standard protocol: 160 mM tracrRNA + 160 mM crRNA (Dharmacon), equal volume mix well 37 C, 30 min (80 mM sgRNA); 80 mM sgRNA + 40 mM Cas9 Protein equal volume mix well 37 C 10 min (20 mM RNPs); leave on ice, each electroporation 10 mL of RNPs mix with 10 mL Opti-MEM with C57B6/J embryos. Standard electroporation: two pulses 30V for 3 ms interval 100 ms. Embryos were transferred into pseudo-pregnant females.
Bone Marrow Chimeras WT CD45.1, or Rag2 À/À , or Tcrb À/À where indicated, were lethally irradiated with 1,100 rads gamma-irradiation (split dose separated by 3 h) and then i.v. injected with relevant BM cells. BM was harvested by flushing the tibia and femurs. For T cell depletion (when necessary), 250 mg of anti-CD4 GK1.5 (BioXcell) was injected i.v. at day À1 and day 0.
Retroviral Constructs and Transductions
Murine HVEM and Bcl2 retroviral constructs were made by inserting the mouse open reading frame into the MSCV2.2 retroviral vector followed by an internal ribosome entry site (IRES) and Thy1.1 as an expression marker. Hvem point mutations were introduced by quick-change PCR and Hvem truncation was introduced by PCR. Retrovirus was generated by transfecting PLAT-E packaging cell line with 10 mg plasmid DNA and 10 mg Lipofectamine 2000 (Fischer). For transduction of BM, WT, Hvem À/À , or Btla À/À mice were injected i.v. with 3 mg 5-fluorouracil (Sigma). BM was collected after 4 days and cultured in DMEM containing 15% (vol/vol) FBS, antibiotics (penicillin (50 IU/mL) and streptomycin (50 mg/mL); Cellgro) and 10 mM HEPES, pH 7.2 (Cellgro), supplemented with IL-3, IL-6 and stem cell factor (at concentrations of 20, 50 and 100 ng/mL, respectively; Peprotech). Cells were 'spin-infected' twice at days 1 and 2 and were transferred into irradiated recipients on day 3. 
Cell Isolation and Adoptive Transfer
Flow Cytometry
Cells were stained on ice, in 96 round bottom plates in PBS supplemented with 2% FBS and 1mM EDTA. The following antibodies were used: B220 APC-CY7 or BV785 (clone RA3-6B2), IgD FITC (clone 11-26c.2a), GL-7 Pacific Blue (clone GL7), FAS PE-CY7 (clone Jo2), CD38 AlexaFluor647 (clone 90), CD45.1 PERCP-CY5.5, APC (clone A20), CD45.2 BV605, APC-CY7 (clone 104), HVEM PE (clone LH1), BTLA AlexaFluor 647 (8F4), Ephrin-B1 Biotin (polyclonal, R&D), CXCR4 Biotin (clone 2B11/CXCR4), CD86 AlexaFluor647 (clone GL-1), IgG1 FITC (clone RMG1-1), CD138 BV421 (clone 281-2), CD73 PERCP-CY5.5 (clone TY/11.8), CD4 PE-CY7 (clone GK1.5), TCRb Pacific Blue (clone H57-597), CXCR5 BV605 (clone L138D7), PD-1 PE or FITC (clone 29F.1A12), CD40L PE (clone MR1), Va2 PERCP-CY5.5 (clone B20.1), Active caspase-3 (clone C92-605), Fixable viability dye eFluor780 (eBioscience). NP-47-PE (Biosearch technologies). For intracellular staining, cells were fixed and permeabilized using BD Cytofix/Cytoperm kit. EdU was detected with Click-IT Plus EdU kit (Invitrogen). Data were collected on a BD LSRII and analyzed on FlowJo Software. qPCR and RNA Sequencing Hvem primers F: GGAGCTGGGATAGCTGGATTC R: TCTCCTGTTGTTCCTGGAAAGG, Il21 primers F: GCTCCACAAGATG TAAAGGG R: TTATTGTTTCCAGGGTTTGA. Cells were sorted using BD FACSAria II. 10 4 cells or greater were sorted for qPCR and 5 3 10 4 cells were sorted for RNA-sequencing. RNA sequencing was prepared using Ovation RNA-seq System V2 from Nugen, KAPA Hyper prep labeling kit, NEXTflex DNA barcodes Adapter kit from Bioo Scientific. 100 bp paired end was run on HiSeq4000 at UCSF Institute for Human Genetics. Data were run through STAR alignment and Deseq2.
GSEA and Gene Ontology GSEA analysis (v3.0) through the BROAD was performed using standard settings: 1000 number of permutations, collapsed data to gene symbols, permutation type phenotype, enrichment statistic weighted. Data for Rapamycin sensitive DEC205-WT GC B cell genes were accessed (Ersching et al., 2017) and significant genes, defined as padj < 0.01 with > 2-fold increased expression in untreated v. Rapa treated, were made into a manually curated gene list. Yu Myc targets UP was a premade GSEA gene list. Gene ontology was performed using Enrichr platform (Kuleshov et al., 2016) .
NP V H 186.2 Mutation Analysis
For bulk GC sequencing: PCR reaction 1. PCR1 F primer: CATGGGATGGAGCTGTATCATGC R primer: CTCACAAGAGTCCGA TAGACCCTG PCR2 (nested) F primer: GGTGACAATGACATCCACTTTGC R primer: GACTGTGAGAGTGGTGCCTTG and the blunt end cloned into TOPO vector. Plates were sent to TacGen for plasmid prep and Sanger sequencing (Bannard et al., 2016 (Yang et al., 2012) . Data were analyzed using IgBLAST and the frequency of W33L were counted in non-frame shifted IGHV1-72*01 sequences.
Tfh Cell CD40L Surface Mobilization Tfh cells were generated by transferring OT-II into WT mice on day À1 and immunizing retro-orbitally with 2 3 10 8 SRBCs (Colorado Serum Company) conjugated to 10 mg (0.85 mg/mL) HEL-OVA and mixed with 150 mg (1 mg/mL) poly I:C (GE Healthcare) pre-heated for 10 min at 60 C in a total volume of 350 mL on day 0. On day 3, spleens were harvested and CD4 + T cells were isolated through negative selection by depletion with anti-CD8a biotin, anti-CD11c biotin, and anti-CD19 biotin antibodies and EasySep Mouse Streptavidin RapidSpheres (Stemcell) in complete RPMI. For B cells, spleens were harvested from WT or Hvem À/À mice. Splenocytes were CTV labeled at 0.5 mM and pulsed with 10 mM, 2 mM, 0.4 mM, or 0.08 mM OVA 323-339 peptide (GenScript) antigen or no antigen for 2 h at 37 C. The splenocytes were all washed three times and 8 3 10 5 splenocytes were combined with 4 3 10 5 CD4 + T cells in a 96-well round bottom plate. To facilitate detection of surface exposed CD40L, the cells were incubated in the presence of 1 mg/mL anti-CD40L PE antibody as previously described (Gardell and Parker, 2017; Koguchi et al., 2007) . After 30 or 60 min incubation at 37 C, T cells were harvested, stained, and analyzed on the LSRII flow cytometer. Anti-CD11c biotin antibody and EasySep Mouse Streptavidin RapidSpheres (Stemcell) were used to deplete dendritic cells in two experiments with no differing results. mRNA used was optimized for each T cell donor and mRNA preparation by performing multiple transfections with titrated mRNA amounts, then assessing total BTLA expression after 24 h by staining with AlexaFluor 647-conjugated anti-BTLA (BioLegend, 344520) and comparing to Quantum AlexaFluor 647 MESF calibration beads (Bangs Laboratories) by flow cytometry. Conditions giving $10,000 transfected BTLA/cell were selected for imaging.
Human Tfh Cell Isolation
Human Tfh cells were isolated from tonsils provided by UK National Health Service Blood and Transplant. Tissue was kept on ice prior to use and processed within 3 h of surgery. Tonsils were washed in ice-cold Hank's balanced salt solution (HBSS; GIBCO) supplemented with 2% FCS, 5% penicillin-streptomycin solution (GIBCO), and 500 mg/mL normocin (Invivogen). Whole tonsils were partially submerged in cold, supplemented HBSS and dissected into pieces 1-5 mm in size using a sterile scalpel. Tissue fragments were separated into multiple 70 mm cell strainers and crushed using a 20 mL syringe plunger, then washed with cold, supplemented HBSS. Strained samples were pooled and passed through a 40 mm cell strainer then pelleted at 400 g for 10 min and resuspended in 15 mL cold, supplemented HBSS. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient centrifugation. Total CD4 + T cells were isolated from the PBMC fraction using the EasySep CD4 + isolation kit (StemCell Technologies) and kept on ice in supplemented HBSS. Cells were immediately stained with anti-CXCR5 conjugated to either AlexaFluor 488 (BD Biosciences, 558112) or PE/Cy7 (BioLegend, 356923) depending on the downstream application, washed, and the CXCR5 high population sorted using a FACSAria III cell sorter (BD Biosciences). Isolated Tfh cells were resuspended at 5 3 10 6 /mL in supplemented RPMI-1640 and cultured for 3 h at 37 C, 5% CO 2 before being used for imaging. A small number of cells were retained and stained with anti-CXCR5 and anti-PD1 conjugated to AlexaFluor 488 (BioLegend, 329935) 
Supported Lipid Bilayer Preparation and Use
Supported lipid bilayers (SLB) were prepared as described previously (Choudhuri et al., 2014) . Briefly, micelles of 1,2-dioleoyl-snglycero-3-phosphocholine (Avanti Polar Lipids Inc.) supplemented with 12.5% 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl]-Ni (Avanti Polar Lipids Inc.) were flowed onto glass coverslips hydroxylated with piranha solution, plasma cleaned, and affixed with adhesive 6-lane chambers (Ibidi). SLBs were blocked and washed, then incubated with recombinant His-tagged proteins of interest (produced in-house with the exception of HVEM-Fc-His, which was a gift from Prof. Simon Davis, University of Oxford) at the requisite concentrations to achieve the desired density: 30 molecules/mm 2 for UCHT1-FaB, 200 molecules/mm 2 for ICAM1, 100 molecules/mm 2 for CD80, 35 molecules/mm 2 for HVEM-Fc-His, and 100 molecules/mm 2 for CD40. The specific combination of unconjugated proteins or proteins conjugated to different dyes (AlexaFluors 405, 488, 568, and 657) was varied to suit the demands of each experiment. Within 2 h of preparation, SLBs were pre-warmed to 37 C and cells were infused into the SLB chambers at $5 3 10 5 /lane for CD4 + cells or $1 3 10 5 /lane for Tfh cells. Samples were either incubated for 3 or 15 min at 37 C then fixed with warm 4% para-formaldehyde in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl 2 , pH 6.9) for 10 min, or imaged live. In experiments involving labeling of transfected BTLA-SNAP-tag, cells were incubated with 0.5 mM SNAP-Cell 647-SiR ligand (New England BioLabs) in supplemented RPMI-1640 for 30 min at 37 C, washed 3 times, and incubated for a further 30 min prior to addition to SLBs.
Immunofluorescence Staining
Fixed cell samples were exposed to a second round of fixation in PHEM buffer with 2% PFA and 3% BSA (bovine serum albumin) for 10 min at room temperature in order to reduce non-specific adsorption of probing antibodies to the coverslip. Samples were washed 3 times with PHEM buffer, permeabilized with 0.1% saponin in PHEM buffer for 15 min, then washed 3 more times with PHEM buffer. Samples were then quenched with 100mM glycine for 20 min and blocked with 6% BSA in PHEM buffer for 1 h before washing 3 times with PHEM buffer. Samples were then incubated with the appropriate primary rabbit antibody (anti-SHP1, Santa Cruz Biotechnology, sc-287; anti-SHP2, Santa Cruz Biotechnology, sc-280; anti-pY493 ZAP70, Cell Signaling Technology, 2704; anti-pT538 PKCq, Cell Signaling Technology, 9377) in PHEM buffer with 0.02% saponin, 3% BSA for 1 h. Washing was performed 3 times with PHEM buffer, 0.1% saponin, 3% BSA with 2 min between each wash, before incubating with goat anti-rabbit F(ab')2 conjugated to AlexaFluor 568 (ThermoFisher Scientific, A-21069) in PHEM buffer with 0.02% saponin, 3% BSA for 45 min. Samples were finally washed 5 times with PHEM buffer, 0.1% saponin, 3% BSA with 2 min between each wash before imaging. A sample stained using only secondary antibody was included in each experiment as a background control.
TIRF and Confocal Imaging TIRF imaging was performed on an Olympus cellTIRF-4Line system using a 150x (NA 1.45) oil objective. Imaging of live samples was performed at 37 C, and of fixed samples at room temperature. Confocal imaging was performed on a 37 C-controlled Olympus FV1200 confocal microscope using a 20x (NA 0.75) air objective.
Image Analysis
All image analysis was performed using the ImageJ software. Thresholded IRM images were used to define the contact area of each cell, and all pixels therein used to calculate the mean fluorescence intensity (MFI) for a given channel. Pearson colocalization coefficients (PCCs) were also calculated only for IRM-defined contact areas using the Coloc 2 plugin to perform pixel intensity correlation between channels. Identification and tracking of cells for comparison of adhesion and movement was performed using the TrackMate plugin, with total cells detected from bright field images and those forming contacts identified through IRM images. Cells were qualitatively assigned as forming synapses or kinapses based on the relative centrality and symmetry of the predominant UCHT1 and ICAM1 signals. Synapses were defined as having approximately central UCHT1 accumulations completely surrounded by a ring of ICAM1; kinapses as having a highly polarized UCHT1 accumulation with ICAM1 adjacent but not surrounding. Cells not fitting either category were defined as unassigned.
In Situ Analysis of Interaction of SHP1 and SHP2 with PD-1 Supported lipid bilayers presenting relevant ligands were prepared as described above. Biotin-CAP-phosphatidylethanolamine was used at a 0.04 molar percentage to that of dioleoylphosphatidylcholine (DOPC). Monobiotinylated Okt3 (anti-CD3 antibody, from Ebiosciences) was used at 0.5 mg/mL. The following ligands were presented on the bilayer by means of coordination chemistry between DOGS-NTA and poly-Histidine tag: 123-His ICAM1 ectodomain at $200 molecules/mm 2 ; 123-His CD58 ectodomain at $300 molecules/mm 2 ; and 123-His PDL1 ectodomain at $300 molecules/mm 2 . Freshly isolated human CD8 + T cells were electroporated with mRNA encoding PD-1 GFP or PD-1 Y248F GFP and cultured for $8 h (Zhao et al., 2006) . Cells were introduced into the flow-cells containing lipid bilayers at 37 C and fixed after 10 min by flowing in pre-warmed 2% EM-grade formic acid in PBS. SHP1/2 staining was performed as described above. Images were acquired on a Nikon Eclipse Ti inverted fluorescence microscope using an Apo TIRF 1003 1.49 NA oil objective. Diode lasers (488 nm, 561 nm and 641 nm, from Coherent) were used for TIRF illumination at the plane of bilayer. An AOTF (from Solamere Technologies) was used for choosing appropriate excitation wavelengths. A xenon arc lamp (from Newport) filtered at 490 nm was used for reflection imaging of cell contacts with the bilayer. Nikon perfect focus systemÒ was used to achieve consistent illumination and also to compensate for axial chromatic aberration. NIS-Elements software (from Nikon) was used for hardware control of the microscope, filter and shutter wheels, AOTF, and the EMCCD camera (Andor DU-897 X-4654) during image acquisition. EMCCD camera was operated in the normal gain mode and well under saturation. Custom written macros were used for automated image analysis in ImageJ 1.44o (from NIH). Cell-boundaries were defined based on segmented ('Default' algorithm in ImageJ) reflection images. Background subtracted images were used for calculating average fluorescence intensity from each cell. PCC values between thresholded green and far-red channels ('MaxEntropy' algorithm in ImageJ) were calculated for each cell to quantitatively measure the extent of colocalization. Cluster statistics were computed using the 'Analyze Particles' routine in ImageJ after thresholding the images using the 'MaxEntropy' algorithm. Statistical significance was assessed by Mann-Whitney test using the GraphPad Prism5 software.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical tests were done with GraphPad Prism software. The appropriate statistical test for each experiment is noted in the figures.
DATA AND CODE AVAILABILITY
Raw and processed data files for RNA sequencing analysis have been deposited in the NCBI Gene Expression Omnibus under accession number GEO: GSE130095.
